 |
Vol.42 No.7 contents | Japanese/English |
 | Full Text of PDF (87K) Article in Japanese |
- -
Is a Standard Therapy Against IIIA N2 NSCLC Induction Chemotherapy Plus Surgery?
Con: Nobuyuki Yamamoto1, Gyo Asai1, Masako Ebisawa1, Masahiro Endo1, Toshiaki Takahashi11Shizuoka Cancer Center Thoracic Oncology, Japan.
It was described in PDQ or NCCN guideline in US that one of the standard treatment for patients with respectable IIIA N2 non-small cell lung cancer (NSCLC) is induction chemotherapy plus surgery. However, we do not think that induction chemotherapy plus surgery is established as standard therapy in Japan because clinical trials registered sufficient patients have been conducted in Japan and the only randomized controlled trial compared induction chemotherapy plus surgery with surgery alone in Japan was negative result. The recent large scale randomized trial reported Depierre showed that induction chemotherapy was effective against early stage NSCLC patient but not effective for patients with N2 NSCLC. At present, the randomized controlled trials evaluated a meaning of an additional surgery have been conducted in US or Europe and as a result, it is possible that chemoradiotherapy becomes a standard therapy of respectable IIIA N2 NSCLC. Because induction chemotherapy plus surgery becomes a standard therapy for patients with respectable IIIA N2 NSCLC in Japan, I think that there is need for at least one clinical trial that is registered sufficient patients and showed usefulness of induction chemotherapy and is conducted in Japan.
JJLC 42 (7): 782-785, 2002
